Aquestive Therapeutics (NASDAQ:AQST) Releases Earnings Results, Misses Estimates By $0.05 EPS

Posted by Don Miller on Mar 6th, 2025

Aquestive Therapeutics (NASDAQ:AQST – Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05), Zacks reports. The company had revenue of $11.87 million during the quarter, compared to analysts’ expectations of $13.11 million. Aquestive Therapeutics updated its FY 2025 guidance to EPS.

Aquestive Therapeutics Price Performance

Shares of NASDAQ:AQST opened at $2.79 on Thursday. The stock has a market capitalization of $254.39 million, a P/E ratio of -6.20 and a beta of 2.76. The business has a 50-day moving average of $3.13 and a two-hundred day moving average of $4.13. Aquestive Therapeutics has a fifty-two week low of $2.24 and a fifty-two week high of $6.23.

Analyst Upgrades and Downgrades

Several brokerages recently commented on AQST. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a research report on Friday, December 20th. Cantor Fitzgerald started coverage on Aquestive Therapeutics in a report on Tuesday, December 17th. They set an “overweight” rating and a $17.00 price target on the stock. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $11.00.

Check Out Our Latest Stock Report on Aquestive Therapeutics

About Aquestive Therapeutics

(Get Free Report)

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.